Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Tentori CA, Zhao LP, Tinterri B, Strange KE, Zoldan K, Dimopoulos K, Feng X, Riva E, Lim B, Simoni Y, Murthy V, Hayes MJ, Poloni A, Padron E, Cardoso BA, Cross M, Winter S, Santaolalla A, Patel BA, Groarke EM, Wiseman DH, Jones K, Jamieson L, Manogaran C, Daver N, Gallur L, Ingram W, Ferrell PB, Sockel K, Dulphy N, Chapuis N, Kubasch AS, Olsnes AM, Kulasekararaj A, De Lavellade H, Kern W, Van Hemelrijck M, Bonnet D, Westers TM, Freeman S, Oelschlaegel U, Valcarcel D, Raddi MG, Grønbæk K, Fontenay M, Loghavi S, Santini V, Almeida AM, Irish JM, Sallman DA, Young NS, van de Loosdrecht AA, Adès L, Della Porta MG, Cargo C, Platzbecker U, Kordasti S; i4MDS consortium. Tentori CA, et al. Among authors: kordasti s. Hemasphere. 2024 May 15;8(5):e64. doi: 10.1002/hem3.64. eCollection 2024 May. Hemasphere. 2024. PMID: 38756352 Free PMC article.
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A; GenoMed4All, Synthema, GESMD, FISIM, and EuroBloodNET; Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG. Tentori CA, et al. Among authors: kordasti s. J Clin Oncol. 2024 May 9:JCO2302175. doi: 10.1200/JCO.23.02175. Online ahead of print. J Clin Oncol. 2024. PMID: 38723212
Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms.
Winter S, Schneider M, Oelschlaegel U, Maggioni G, Riva E, Raddi MG, Bencini S, Peruzzi B, Choy D, Antunes Dos Reis R, Güse E, Lischer C, Vera J, Timms JA, Sompairac N, Sockel K, Poloni A, Tunger A, Della Porta MG, Santini V, Schmitz M, Platzbecker U, Kordasti S. Winter S, et al. Among authors: kordasti s. Leukemia. 2024 Apr 17. doi: 10.1038/s41375-024-02249-z. Online ahead of print. Leukemia. 2024. PMID: 38632316 No abstract available.
Marginal Zone Lymphoma Manifesting as Macrophage Activation Syndrome: A Case Report.
Ebrahimi N, Noor SM, Kordasti S, Akhtari M, Norouzi S, Vakhshoori M, Abdipour A. Ebrahimi N, et al. Among authors: kordasti s. J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241244732. doi: 10.1177/23247096241244732. J Investig Med High Impact Case Rep. 2024. PMID: 38577998 Free PMC article.
A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.
Zareian N, Eremin O, Pandha H, Baird R, Kwatra V, Funingana G, Verma C, Choy D, Hargreaves S, Moghimi P, Shepherd A, Lobo DN, Eremin J, Farzaneh F, Kordasti S, Spicer J. Zareian N, et al. Among authors: kordasti s. Exp Biol Med (Maywood). 2024 Jan 31;249:10021. doi: 10.3389/ebm.2024.10021. eCollection 2024. Exp Biol Med (Maywood). 2024. PMID: 38463391 Free PMC article. Clinical Trial.
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Gurnari C, Pascale MR, Vitale A, Diral E, Tomelleri A, Galossi E, Falconi G, Bruno A, Crisafulli F, Frassi M, Cattaneo C, Bertoli D, Bernardi M, Condorelli A, Morsia E, Poloni A, Crisà E, Caravelli D, Triggianese P, Brussino L, Battipaglia G, Bindoli S, Sfriso P, Caroni F, Dragani M, Mallegni F, Pilo F, Firinu D, Curti A, Papayannidis C, Olivieri A, Kordasti S, Albano F, Pane F, Musto P, Bocchia M, Lugli E, Breccia M, Frigeni M, Dagna L, Greco R, Franceschini F, Campochiaro C, Cantarini L, Voso MT. Gurnari C, et al. Among authors: kordasti s. Am J Hematol. 2024 Feb;99(2):254-262. doi: 10.1002/ajh.27169. Epub 2023 Dec 18. Am J Hematol. 2024. PMID: 38108611
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products.
O'Brien Gore C, Billman A, Hunjan S, Colebrook J, Choy D, Li W, Haynes J, Wade J, Hobern E, McDonald L, Papa S, Brugman M, Kordasti S, Montiel-Equihua C. O'Brien Gore C, et al. Among authors: kordasti s. Mol Ther Oncolytics. 2023 Nov 10;31:100749. doi: 10.1016/j.omto.2023.100749. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 38075248 Free PMC article.
LYVE-1+ macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer.
Anstee JE, Feehan KT, Opzoomer JW, Dean I, Muller HP, Bahri M, Cheung TS, Liakath-Ali K, Liu Z, Choy D, Caron J, Sosnowska D, Beatson R, Muliaditan T, An Z, Gillett CE, Lan G, Zou X, Watt FM, Ng T, Burchell JM, Kordasti S, Withers DR, Lawrence T, Arnold JN. Anstee JE, et al. Among authors: kordasti s. Dev Cell. 2023 Sep 11;58(17):1548-1561.e10. doi: 10.1016/j.devcel.2023.06.006. Epub 2023 Jul 12. Dev Cell. 2023. PMID: 37442140 Free article.
88 results